A new roadmap for drug development for Alzheimer's disease

Affiliations

¹ Aristea Translational Medicine, 5011 Mountain View Road #63, Carrabassett Valley, Maine O4947, USA, and a Clinical Consultant in the Drug Design and Development Section, Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, Maryland 21224, USA.
² Drug Design and Development Section, Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore Maryland 21224, USA.
³ Department of Internal Medicine, Rehabilitation, and Geriatrics, University of Geneva, Medical School, University Hospitals of Geneva, Thonex-Geneva, Switzerland.
⁴ Departments of Psychiatry, Neurology, and Gerontology, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA.
⁵ Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, Maryland 21224, USA.

Comment

Robert E Becker et al. Nat Rev Drug Discov. 2014 Feb.

. 2014 Feb;13(2):156.

doi: 10.1038/nrd3842-c2. Epub 2013 Dec 20.

¹ Aristea Translational Medicine, 5011 Mountain View Road #63, Carrabassett Valley, Maine O4947, USA, and a Clinical Consultant in the Drug Design and Development Section, Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, Maryland 21224, USA.
² Drug Design and Development Section, Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore Maryland 21224, USA.
³ Department of Internal Medicine, Rehabilitation, and Geriatrics, University of Geneva, Medical School, University Hospitals of Geneva, Thonex-Geneva, Switzerland.
⁴ Departments of Psychiatry, Neurology, and Gerontology, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA.
⁵ Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, Maryland 21224, USA.

No abstract available

Comment on

Sting of Alzheimer's failures offset by upcoming prevention trials.
Mullard A. Mullard A. Nat Rev Drug Discov. 2012 Sep;11(9):657-60. doi: 10.1038/nrd3842. Nat Rev Drug Discov. 2012. PMID: 22935790 No abstract available.

1. Mullard A. Sting of Alzheimer’s failures offset by upcoming prevention trials. Nature Rev. Drug Discov. 2012;11:657–660. - PubMed
1. Aisen PS, Vellas B, Hampel H. Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer’s disease. Nature Rev. Drug Discov. 2013;12:324. - PubMed
1. Buchhave P, et al. Cerebrospinal fluid levels of β-amyloid 1–42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch. Gen. Psychiatry. 2012;69:98–106. - PubMed
1. Rodrigue KM, et al. β-Amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology. 2012;78:387–395. - PMC - PubMed
1. Pike KE, et al. Cognition and β-amyloid in preclinical Alzheimer’s disease: data from the AIBL study. Neuropsychologia. 2011;49:2384–2390. - PubMed